Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket

29d ago, source: Hosted on MSN

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter results. Salarius Pharmaceuticals posted a net loss of $0.9 million ...

Salarius Pharmaceuticals Inc SLRX

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

1mon ago, source: Business Insider

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options. Salarius’ product portfolio includes ...

Salarius: Q4 Earnings Snapshot

1mon ago, source: The Washington Post

HOUSTON — HOUSTON — Salarius Pharmaceuticals, Inc. (SLRX) on Friday reported a loss of $882,000 in its fourth quarter. The Houston-based company said it had a loss of 22 cents per share.

Dada Nexus, Salarius Pharmaceuticals And 3 Stocks To Watch Heading Into Monday

1mon ago, source: Benzinga.com

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: Salarius Pharmaceuticals, Inc. SLRX posted a net loss of $0.9 ...

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

1mon ago, source: Stockhouse

The Ewing sarcoma trial is currently active but is not enrolling additional patients. Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients ...

Salarius Pharmaceuticals Inc.

27d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

1mon ago, source: Yahoo Finance

HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop ...